Reader looking for guidelines/policies on continuous infusion vesicants for assessments.
Parran
L
L
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002408:Catheters, Indwelling / Q000009:adverse effects*; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007509:Irritants / Q000008:administration & dosage* / Q000009:adverse effects; D008991:Monitoring, Physiologic / Q000451:nursing* / Q000592:standards; D009369:Neoplasms / Q000188:drug therapy / Q000451:nursing*; D009730:Nursing Assessment / Q000592:standards; D009859:Oncology Nursing / Q000379:methods; D016134:Organizational Policy
D000970:Antineoplastic Agents; D007509:Irritants